Searched for
BOEHRINGER
Boehringer Ingelheim, Viyash Scientific enter pet healthcare pact in IndiaGerman biopharma giant Boehringer Ingelheim is partnering with Viyash Scientific to bring its pet healthcare products to India. This collab...- Lupin shares in focus on acquisition of 3 anti-diabetes trademarks to strengthen diabetes portfolioLupin Share Price: Lupin has acquired the anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim to bolster ...
- Lupin acquires two diabetes brands from Boehringer IngelheimLupin has been marketing Ondero and Ondero Met since 2015 in the Indian market as part of a co-marketing agreement with Boehringer Ingelhei...
- Boehringer Ingelheim appoints Gagandeep Singh as MD, Head of Human Pharma IndiaBoehringer Ingelheim on Monday said that the company has appointed Gagandeep Singh as Managing Director and Head of Human Pharma India, eff...
- Boehringer Ingelheim obtains interim injunction against four Indian drug cos from selling its diabetes drugBI said the injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making,...
- Boehringer Ingelheim India seeks system to keep tab on patent infringementIn terms of focus areas in the country, she said the drug firm is focussed on providing solutions for non communicable diseases like diabet...
- Boehringer Ingelheim's diabetes pill Jardiance gets CDSCO nod for use against heart failureGerman drug maker Boehringer Ingelheim has won approval from the Indian drug regulator to market its top-selling type-2 diabetes medication...
- Lupin Q1 results: Net profit jumps 5-fold to Rs 542 croreThe significant jump in June quarter net profit was on account of robust sales and income received from biopharmaceutical firm Boehringer I...
- Lupin receives $50 million from Boehringer Ingelheim for achievement of key milestonesIn a regulatory filing Lupin announced "the achievement of key milestones for Lupin's MEK inhibitor compound (LNP3794) that is planned for ...
- Sanofi, Boehringer Ingelheim close business swap in IndiaSanofi is excited to embrace the incoming CHC brands and people associated with this business, as this is in line with objective of boostin...
- Boehringer Ingelheim India and Lupin enter agreement to market diabetes drugIMS values the Indian diabetes market is at Rs9,003 crore and has recorded it as growing at 19.5%, according to a release by Lupin.
- Boehringer Ingelheim hid key info in petition, says GennovaGennova’s stroke medicine — tenecteplase — was approved by an expert committee of the Central Drugs Standard Control Organisation (CDSCO) i...
- Gennova moves application to dismiss Boehringer’s case on stroke medicineGennova alleges that Boehringer did not disclose a PIL still pending with another bench at the court on the same objections when it filed i...
- Battle over stroke medicine between Boehringer and Gennova heats up at courtGennova didn’t follow the ethical guidelines issued by the Indian Council of Medical Research (ICMR) while designing its clinical study for...
- Action between Boehringer Ingelheim and Gennova over stroke medicine moves to courtThe approval of tenectaplase for use in stroke patients has been a point of contention between German drug maker Boehringer Ingelheim and G...
- Sanofi, Boehringer Ingelheim seek CCI nod for $25-billion global asset swap dealThe commission will review if the two companies swapping their businesses will cause any adverse impact on the local competition.
- Germany’s Boehringer denied patent on HIV drugThe Indian Patent Office has denied Germany's Boehringer Ingelheim a patent on its key HIV drug, Nevirapine, for a version sold as Viramune...
- Zydus Cadila loses two popular brandsDulcolax and Buscopan had been present for the past many decades in India, initially through an agreement that Boehringer Ingelheim had wit...
- Anti-diabetes Molecules: Connexios inks licence deal with German pharma major Boehringer IngelheimFor Connexios, this sale of its anti-diabetes molecules to Boehringer Ingelheim is the first out-licensing deal by an Indian life-sciences ...
- Boehringer Ingelheim, Eli Lilly launch Linagliptin tabletsBoehringer Ingelheim India and Eli Lilly and Company India (Lilly) today said they have launched Linagliptin tablets used for treating diab...
Load More
